Seroatlas · Human Serome Atlas

CLDN14

Claudin-14

Also known as: CLD14_HUMAN, DFNB29

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O95500
Gene
CLDN14
Ensembl
ENSG00000159261
Chromosome
21
Canonical length
239 aa
Protein class
Disease related genes, Human disease related genes, Predicted membrane proteins
Subcellular location
Vesicles

OverviewNCBI Gene

Tight junctions represent one mode of cell-to-cell adhesion in epithelial or endothelial cell sheets, forming continuous seals around cells and serving as a physical barrier to prevent solutes and water from passing freely through the paracellular space. These junctions are comprised of sets of continuous networking strands in the outwardly facing cytoplasmic leaflet, with complementary grooves in the inwardly facing extracytoplasmic leaflet. The protein encoded by this gene, a member of the claudin family, is an integral membrane protein and a component of tight junction strands. The encoded protein also binds specifically to the WW domain of Yes-associated protein. Defects in this gene are the cause of an autosomal recessive form of nonsyndromic sensorineural deafness. It is also reported that four synonymous variants in this gene are associated with kidney stones and reduced bone mineral density. Several transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jun 2010]

Canonical amino-acid sequenceUniProt

239 residues, UniProt reviewed canonical sequence.

>O95500|CLDN14
     1  MASTAVQLLG FLLSFLGMVG TLITTILPHW RRTAHVGTNI LTAVSYLKGL WMECVWHSTG
    61  IYQCQIYRSL LALPQDLQAA RALMVISCLL SGIACACAVI GMKCTRCAKG TPAKTTFAIL
   121  GGTLFILAGL LCMVAVSWTT NDVVQNFYNP LLPSGMKFEI GQALYLGFIS SSLSLIGGTL
   181  LCLSCQDEAP YRPYQAPPRA TTTTANTAPA YQPPAAYKDN RAPSVTSATH SGYRLNDYV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CLDN14 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
4
Mean surface accessibility (rSASA)
0.39
Highest tissue expression
39 nTPM

Expression across tissuesHPA

Tissue

  • liver: 39 nTPM
  • kidney: 8.4 nTPM
  • pancreas: 0.9 nTPM
  • epididymis: 0.4 nTPM
  • skeletal muscle: 0.4 nTPM
  • appendix: 0.3 nTPM

Single-cell type

  • loop of henle epithelial cells: 118 nCPM
  • epididymal principal cells: 44 nCPM
  • hepatocytes: 34 nCPM
  • distal convoluted tubule cells: 20 nCPM
  • myonuclei: 18 nCPM
  • plasma cells: 18 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • cerebral cortex: 1.8 nTPM
  • amygdala: 1.1 nTPM
  • pons: 0.9 nTPM
  • thalamus: 0.9 nTPM
  • basal ganglia: 0.8 nTPM
  • hippocampal formation: 0.8 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about CLDN14.

Disease | AllUniProt

Conditions CLDN14 is implicated in, by any mechanism.

Disease | GeneticClinVar

20 pathogenic / likely-pathogenic of 196 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.75
gnomAD pLI
0
gnomAD missense Z
0.2
DepMap mean gene effect
0.1
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CLDN14 as an antibody target. Whether an autoantibody or antibody against CLDN14 could matter depends on whether native CLDN14 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CLDN14 is annotated at the cell surface, where native CLDN14 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CLDN14 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/CLDN14. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...